~~<i id='46A6793974'><strike id='46A6793974'><tt id='46A6793974'><pre id='46A6793974'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：focus 2025-09-29 23:24:12 Page View：86

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Treeline, Josh Bilenker's next biotech, is cloaked in mystery
Next article： Medical records are filled with copy

explore

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

What Henrietta Lacks settlement says about racism in medicine

ApaintingofHenriettaLacksHenriettaLacksHouseofHealingForwhatwouldhavebeenHenriettaLacks’103thbirthda

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Vansglutenfreewaffles.USFDAGluten-freebreakfastfans,checkyourfreezertoensurethisnewlyrecalledfrozenw